Showing 1–25 of 184 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Alina Malic, Adriana Niguleanu, Tatyana Osipov
Treatment of tuberculosis (TB) includes various therapeutic regimens with a combination of at least four drugs. Adherence to the treatment regimen is crucial for efficacy outcomes based on the achievement of appropriate drug levels. Drug-resistant () strains are mainly favored by…
Timothy M Walker, James A Watson, David A J Moore, Mike Frick, Euzebiusz Jamrozik
… designs have so far led to the implementation of effective regimens of 1-4 months' duration. Such regimens are a substantial improvement on the previous 6-9 months' duration standard of care but still far too long given potential toxicity and the very low baseline risk of diseas…
Susanna Esposito, Valentina Fainardi, Beatrice Rita Campana, Gaia Giorgia Arnesano, Nicola Principi
…16 years with drug-susceptible TB treated with short-course regimens compared to standard therapy.A shorter treatment regimen, particularly 4-month courses, has been investigated as an alternative to standard therapy in the pediatric population with drug-susceptible TB. Children …
Tushar Garg
…2035. The treatment of MDR- and XDR-TB consists of 4–6 drug regimens for durations of 1–2 years. In this open label, single-group study in 3 sites, the safety and efficacy of a 3-drug regimen, including bedaquiline, linezolid, and pretomanid (BPaL), was assessed for treatment of …
Soham Samajpaty
Mumbai Protocol is a shot in darkness in the field of tuberculosis research. At a time when clinicians around the world are obsessed with rifampicin to an extent of believing that no regimen against tuberculosis can work without it, the Mumbai protocol has opened a new avenue in …
Caterina Davoli, Chiara Rossi, Andrea Ciccarone, Francesca Bertoni, Marina Calamelli, et al.
…t and breastfeeding women. A key difference between the two regimens is the replacement of pretomanid with delamanid in the BDLLfxC. However, limitations remain. Neither BPaLM nor BDLLfxC are recommended in patients with complicated forms of extrapulmonary MDR-TB: central nervous…
Tim Crocker-Buque, Michael A Moso, Justin T Denholm, Kasha P Singh
…afety and efficacy of newer LA-ART and bedaquiline-based TB regimens in this high-risk population. Concerns around the safety of TPT in pregnancy remain unanswered and further prospective research is urgently needed.
Antonio Camargo Martins, Márcia Teixeira Garcia, Mariângela Ribeiro Resende
Standard anti-tuberculosis regimens (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol [RHZE]) remain challenging for critically ill patients and those with a non-functioning gastrointestinal tract. In Brazil, these challenges are amplified by the lack of Intravenous (IV) rifam…
Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori
…rne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial to maintain adequate blood drug level. The emergence and spread of drug-resistantstrains is mainly favored by the inadequate medical management of pati…
M Amiri, M Cheraghi, M J Nasiri, D R Silva, G Sotgiu, et al.
…revious review summarised the evolution and efficacy of the regimens to treat rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), underscoring the persistent need for efficacious shorter treatments. The aim of this scoping review was to explore safety, quality of life (QoL),…
Miriam Abadie, Alexander Kay
…ed therapy, as well as emerging evidence on novel treatment regimens, post-TB complications, and DR-TB medication resistance among PWH. **RECENT FINDINGS:** Treatment for DR-TB has evolved to shorter, all-oral regimens with reduced drug-drug interactions. However, emerging dolut…
Mohammed Alfaqeeh, Prayudi Santoso, Jan-Willem Alffenaar, Ivan S Pradipta
…istance, which compromise treatment efficacy. The treatment regimens for DR-TB include the INH-R regimen, Bedaquiline, Pretomanid, and Linezolid (with or without Moxifloxacin) (BPaL(M) regimen, shorter oral regimen, and longer oral regimen, each tailored to the specific resistanc…
Koushik Mukherjee, Pritam Saha, Kirat Kumar Ganguly, Somjyoti Chakraborty, Swarnali Ghosh, et al.
…ealth threat. Despite advances in diagnostics and treatment regimens, it infects millions annually. It remains a significant global health challenge, particularly due to the appearance of resistance towards anti-tuberculosis drugs (ATD), mainly multidrug-resistant (MDR) and exten…
Marcela Muñóz-Torrico, Norma A. Téllez-Navarrete, Heinke Kunst, Linh Nguyen
…nd when to start anti-TB treatment, discuss the recommended regimens for drug sensitive TB. Establish recommended doses of the primary regimen, and finally recommended treatment adjustment in special situations. Effective and on time tuberculosis treatment is essential for TB con…
Rafael Laniado-Laborı́n
…endations for programmatic management (the short and longer regimens) and one for operational research (the BPaL regimen).
Amira Mahmood, Mohammad Bilal Ashfaq, Catherine Drain, Eoin Melby, Michael Hunter, et al.
…gies: there is now a surge in novel tuberculosis agents and regimens entering human trials. For decades, drug resistant tuberculosis required at least 18 months of second line and third line combination treatments that included injectable agents. In 2022, in response to a growing…
Sonya Krishnan, Robin Avery, Veronica Dioverti, Jeffrey A Tornheim
…. Evidence indicates that short-course, rifamycin-based TPT regimens are associated with less hepatoxicity and improved treatment completion compared to isoniazid. In the transplant population, however, drug-drug interactions limit their use, so isoniazid preventive therapy remai…
Aneeka Chavda, Mark Gilchrist, Toby Capstick, Christabelle Chen, Onn Min Kon
…at associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the …
Chiara Sepulcri, Francesca Saluzzo, Daniele Roberto Giacobbe, Antonio Di Biagio, Daniela Maria Cirillo, et al.
…therapeutic advances. The shift from long, injectable-based regimens to shorter, all-oral regimens has improved outcomes, yet substantial challenges remain in ensuring efficacy, safety, and equitable access. **AREAS COVERED:** We reviewed recent literature (2020-2025) searching …
Akhmad Imron, Yulius Hermanto, Timotius Wira Yudha, Ahmad Rizal, Vycke Yunivita Kusumah Dewi, et al.
…erculosis therapy for TBM, focusing on optimizing treatment regimens. **METHODS:** This literature review primarily draws from studies available in the PubMed and Scopus databases on TBM regimens, focusing on publications that evaluate higher doses or novel drug therapies. Key s…
Gail B Cross
…ew therapeutics, repurposed agents, and shortened treatment regimens. It aims to contextualize key developments within the evolving TB treatment landscape and assess their potential to transform clinical management of both drug-susceptible and drug-resistant disease. **RECENT FI…
Bijan J. Ghassemieh, Masahiro Narita
…ury and a low rate of treatment completion. Rifamycin-based regimens (3 months of once weekly INH and rifapentine, 4 months of daily rifampin, and 3 months of daily INH and rifampin) are now preferred because of their effectiveness, safety, and high treatment completion rates. Pr…
Kara Lukas, Madeleine T Dang, Clare Necas, Vishwanath Venketaraman
…-sensitive and drug-resistant TB, focusing on pharmacologic regimens, diagnostics, and adjunctive therapies. For drug-sensitive TB, a 4-month rifapentine-moxifloxacin regimen has been proven to be non-inferior to the traditional 6-month standard, while optimized pyrazinamide dosi…
Vidya Mave, Mandar Paradkar, Francesca Conradie, Amita Gupta, Anchalee Avihingsanon, et al.
Over the past 80 years, tuberculosis treatment has evolved with the development of all-oral treatments, which are now given for 4-6 months for drug-sensitive tuberculosis and 6-9 months for drug-resistant tuberculosis. Treatment success is often reduced among people with HIV due …
Olga Adriana Căliman-Sturdza
…iagnostics for cerebrospinal fluid (CSF), refined pediatric regimens, and emerging intensified/adjunctive treatments. Narrative synthesis of current guidelines and peer-reviewed articles (priority on 2019–2025), with an emphasis on pathophysiology, diagnostics, treatment (drug-su…